Compare AHMA & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHMA | RNAC |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 217.1M |
| IPO Year | N/A | 2016 |
| Metric | AHMA | RNAC |
|---|---|---|
| Price | $5.85 | $8.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 34.5K | ★ 176.5K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,797,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.02 |
| P/E Ratio | $180.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.25 | $5.98 |
| 52 Week High | $39.50 | $17.42 |
| Indicator | AHMA | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 35.95 | 57.97 |
| Support Level | $5.70 | $6.41 |
| Resistance Level | $9.75 | $10.49 |
| Average True Range (ATR) | 0.54 | 0.81 |
| MACD | 0.24 | 0.14 |
| Stochastic Oscillator | 10.15 | 66.67 |
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.